CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Artemis Therapeutics, Inc.  (INKS)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

INKS's Operating Income Growth by Quarter and Year

Artemis Therapeutics,'s Operating Income results by quarter and year




INKS Operating Income (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - 0.61 0.30 -0.02
III Quarter September 0.20 0.23 0.02 -0.03
II Quarter June 0.21 0.02 -0.02 -0.08
I Quarter March 0.30 0.19 -0.04 -0.03
FY   0.71 1.05 0.26 -0.16



INKS Operating Income third quarter 2018 Y/Y Growth Comment
Artemis Therapeutics, Inc. reported fall in Operating Income in the third quarter by -11.74% to $ 0.20 millions, from the same quarter in 2017.
The decline in the third quarter Artemis Therapeutics, Inc.'s Operating Income compares unfavorably to the Company's average Operating Income rise of 20.18%.

Looking into third quarter results within Biotechnology & Drugs industry 14 other companies have achieved higher Operating Income growth. While Artemis Therapeutics, Inc.' s Operating Income decrease of -11.74% ranks overall at the positon no. 1681 in the third quarter.

Explain Operating Income growth


INKS Operating Income ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - 103.33 % - -
III Quarter September -11.74 % 1050 % - -
II Quarter June 950 % - - -
I Quarter March 57.89 % - - -
FY   - 303.85 % - -

Financial Statements
Artemis Therapeutics,'s third quarter 2018 Operating Income $ 0.00 millions INKS's Income Statement
Artemis Therapeutics,'s third quarter 2017 Operating Income $ 0.00 millions Quarterly INKS's Income Statement
New: More INKS's historic Operating Income Growth >>


INKS Operating Income (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - 165.22 % 1400 % -
III Quarter September -3.33 % 1050 % - -
II Quarter June -30 % -89.47 % - -
I Quarter March -50.82 % -36.67 % - -
FY (Year on Year)   - 303.85 % - -




Operating Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #15
Healthcare Sector #109
Overall #1681

Operating Income Y/Y Growth Statistics
High Average Low
88.24 % 20.18 % -8.51 %
(Mar 31 2017)   (June 30. 2014)
Operating Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #15
Healthcare Sector #109
Overall #1681
Operating Income Y/Y Growth Statistics
High Average Low
88.24 % 20.18 % -8.51 %
(Mar 31 2017)   (June 30. 2014)

Operating Income by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Artemis Therapeutics,'s Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
1566.67 % 335.39 % -90.27 %
(Dec 31 2016)  


INKS's III. Quarter Q/Q Operating Income Comment
In the III. Quarter 2018 Artemis Therapeutics, Inc. reported fall in Operating Income sequentially by -3.33% to $ 0.20 millions, from $ 0.21 millions achived in the previous qaurter.

Those cyclical circumstance that commonly energize III. Quarter 2018 performance, were not able to rescue the III. Quarter for the Artemis Therapeutics, Inc., Atharv Chauhan , Biotechnology & Drugs industry advisor pointed out, he cited certan caution for the INKS's outlook and mentioned that average quarter on quarter Operating Income growth is at 335.39% for Artemis Therapeutics,.

Within Biotechnology & Drugs industry 9 other companies have achieved higher Operating Income quarter on quarter growth. While Artemis Therapeutics,'s Operating Income growth quarter on quarter, overall rank is 1321.


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #10
Healthcare Sector #74
Overall #1321
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #10
Healthcare Sector #74
Overall #1321
Operating Income Q/Q Growth Statistics
High Average Low
1566.67 % 335.39 % -90.27 %
(Dec 31 2016)  


INKS's III. Quarter Q/Q Operating Income Comment
In the III. Quarter 2018 Artemis Therapeutics, Inc. reported fall in Operating Income from the previous quarter by -3.33% to $ 0.20 millions, from $ 0.21 millions achived in the previous qaurter.

Those cyclical circumstance were not able to recover the III. Quarter for the Artemis Therapeutics, Inc., Atharv Chauhan , Biotechnology & Drugs industry advisor said, he cited little skepticism towards INKS's direction.

Within Biotechnology & Drugs industry 9 other companies have achieved higher Operating Income quarter on quarter growth. While Artemis Therapeutics,'s Operating Income growth quarter on quarter, overall rank is 1321.


Artemis Therapeutics,'s 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Operating Income 12 Months Ending $ 1.32 $ 1.35 $ 1.15 $ 1.04 $ 0.73
Y / Y Operating Income Growth (TTM) 81.37 % 158.73 % 140.42 % 307.45 % -
Year on Year Operating Income Growth Overall Ranking # 277 # 144 # 142 # 95 # 0
Seqeuential Operating Income Change (TTM) -1.78 % 16.81 % 11.07 % 42.33 % 40.12 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1681 # 459 # 539 # 299 # 185




Cumulative Operating Income growth Comment
With the quarterly Operating Income reported in the Sep 30 2018 period, Artemis Therapeutics,'s cumulative twelve months Operating Income were $ 1 millions, company would post below average annual Operating Income growth of 40.12% year on year, if the fiscal year would end at Sep 30 2018.
A slow-down in the Artemis Therapeutics,'s Operating Income growth from the 0.21% growth in Jun 30 2018.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 144 to 277.

Operating Income TTM Q/Q Growth Statistics
High Average Low
88.24 %
20.18 %
-8.51 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 15
Healthcare Sector # 24
Overall # 277

Operating Income TTM Y/Y Growth Statistics
High Average Low
307.45 %
171.99 %
81.37 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 109
S&P 500 # 1681
Cumulative Operating Income growth Comment
With the quarterly Operating Income reported in the Sep 30 2018 period, Artemis Therapeutics,'s cumulative twelve months Operating Income were $ 1 millions, company would post below average annual Operating Income growth of 81.37% year on year, if the fiscal year would end at Sep 30 2018.
A slow-down in the Artemis Therapeutics,'s Operating Income growth from the 0.21% growth in Jun 30 2018.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 144 to 277.

Operating Income TTM Q/Q Growth Statistics
High Average Low
88.24 %
20.18 %
-8.51 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 15
Healthcare Sector # 24
Overall # 277

Operating Income TTM Y/Y Growth Statistics
High Average Low
307.45 %
171.99 %
81.37 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 109
S&P 500 # 1681




Other Operating Income Growth
Biotechnology & Drugs Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
INKS's Operating Income Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for INKS's Competitors
Operating Income Growth for Artemis Therapeutics,'s Suppliers
Operating Income Growth for INKS's Customers

You may also want to know
INKS's Annual Growth Rates INKS's Profitability Ratios INKS's Asset Turnover Ratio INKS's Dividend Growth
INKS's Roe INKS's Valuation Ratios INKS's Financial Strength Ratios INKS's Dividend Payout Ratio
INKS's Roa INKS's Inventory Turnover Ratio INKS's Growth Rates INKS's Dividend Comparisons



Companies with similar Operating Income fall for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2018
Universal Health Services Inc -0.06 %$ -0.057 millions
Bio-techne Corp -1.03 %$ -1.030 millions
Msa Safety Incorporated -1.51 %$ -1.512 millions
Healthcare Services Group Inc -1.70 %$ -1.702 millions
Zynex Inc -3.92 %$ -3.918 millions
Amgen Inc. -4.76 %$ -4.756 millions
West Pharmaceutical Services Inc -4.85 %$ -4.851 millions
Psychemedics Corp -5.02 %$ -5.018 millions
Lifevantage Corp -5.29 %$ -5.293 millions
Utah Medical Products Inc -5.92 %$ -5.920 millions
Atrion Corp -6.29 %$ -6.290 millions
Prestige Consumer Healthcare Inc. -6.87 %$ -6.871 millions
Djo Finance Llc -8.67 %$ -8.673 millions
Lemaitre Vascular Inc -8.71 %$ -8.708 millions
Hologic Inc -9.41 %$ -9.415 millions
Magellan Health Inc -9.92 %$ -9.920 millions
Artemis Therapeutics, Inc. -10.57 %$ -10.573 millions
Hca Healthcare, Inc. -13.47 %$ -13.472 millions
Mednax, Inc. -13.66 %$ -13.660 millions
Conmed Corp -14.46 %$ -14.462 millions
Anika Therapeutics, Inc. -16.52 %$ -16.516 millions
Community Health Systems Inc -17.78 %$ -17.778 millions
Standard Diversified Inc. -18.14 %$ -18.140 millions
Meridian Bioscience Inc -19.27 %$ -19.269 millions
Henry Schein Inc -22.30 %$ -22.300 millions
Eagle Pharmaceuticals, Inc. -26.24 %$ -26.244 millions
Owens & Minor Inc -28.02 %$ -28.021 millions
Gilead Sciences Inc -31.19 %$ -31.191 millions
Mettler Toledo International Inc -31.52 %$ -31.518 millions
Lifepoint Health, Inc. -35.00 %$ -35.004 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ZGSI's Profile

Stock Price

ZGSI's Financials

Business Description

Fundamentals

Charts & Quotes

ZGSI's News

Suppliers

ZGSI's Competitors

Customers & Markets

Economic Indicators

ZGSI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071